KNTP.F Stock Overview
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in researching, developing, and commercializing therapeutic drugs for dermatology and tumors indications with the unmet medical needs in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Kintor Pharmaceutical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.14 |
| 52 Week High | HK$0.61 |
| 52 Week Low | HK$0.10 |
| Beta | -0.19 |
| 1 Month Change | 40.00% |
| 3 Month Change | n/a |
| 1 Year Change | -80.82% |
| 3 Year Change | -96.31% |
| 5 Year Change | n/a |
| Change since IPO | -88.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| KNTP.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.4% | -1.5% | -0.7% |
| 1Y | -80.8% | 0.1% | 22.3% |
Return vs Industry: KNTP.F underperformed the US Biotechs industry which returned -1% over the past year.
Return vs Market: KNTP.F underperformed the US Market which returned 22.8% over the past year.
Price Volatility
| KNTP.F volatility | |
|---|---|
| KNTP.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KNTP.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine KNTP.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 225 | Youzhi Tong | www.kintor.com.cn |
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the People’s Republic of China and internationally. The company’s products pipeline include Proxalutamide, a second generation androgen receptor (AR) antagonist for the treatment of metastatic castration-resistant prostate cancer, AR positive breast cancer, and COVID-19; and Pyrilutamide, an AR antagonist for the androgenetic alopecia (AGA) and acne vulgaris treatment. Its products pipeline comprises ALK-1 antibody for the treatment of metastatic hepatocellular carcinoma (HCC) and various solid tumours; GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris; and PD-L1/TGF-ß, a dual target antibody to treat non-small cell lung cancer, biliary tract cancer, triple negative breast cancer, and HPV-associated tumours.
Kintor Pharmaceutical Limited Fundamentals Summary
| KNTP.F fundamental statistics | |
|---|---|
| Market cap | US$53.20m |
| Earnings (TTM) | -US$146.50m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs KNTP.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KNTP.F income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥42.23m |
| Gross Profit | -CN¥42.23m |
| Other Expenses | CN¥1.02b |
| Earnings | -CN¥1.06b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.37 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 53.9% |
How did KNTP.F perform over the long term?
See historical performance and comparison